Title:
ANTI-TUMOR IMMUNE RESPONSE ENHANCER
Document Type and Number:
WIPO Patent Application WO/2024/057892
Kind Code:
A1
Abstract:
The present invention addresses the problem of providing a means for maintaining and enhancing the anti-tumor activity of TADC in a tumor microenvironment. It was found that when a composition, "cPLs adjuvant," containing three types of phospholipids is administered, the degree of growth of a tumor transplanted into a mouse is remarkably reduced. It was also confirmed that immature dendritic cells are cultured in vitro in the presence of the cPLs adjuvant, and then become mature myeloid dendritic cells and induce the production of cytokines.
Inventors:
HASUMI KENICHIRO (JP)
RII KO (JP)
RII KO (JP)
Application Number:
PCT/JP2023/030929
Publication Date:
March 21, 2024
Filing Date:
August 28, 2023
Export Citation:
Assignee:
HASUMI KENICHIRO (JP)
NAT CT CHILD HEALTH & DEV (JP)
NAT CT CHILD HEALTH & DEV (JP)
International Classes:
A61K31/685; A61K39/39; A61K45/00; A61P35/00; A61P37/04; A61P43/00; C12N5/0784
Domestic Patent References:
| WO2015093588A1 | 2015-06-25 | |||
| WO2008052126A2 | 2008-05-02 |
Foreign References:
| JP2019500021A | 2019-01-10 | |||
| JP2019533692A | 2019-11-21 |
Other References:
YU, ANAN ET AL.: "Preferential extemalization of newly synthesized phosphatidylserine in apoptotic U937 cells is dependent on caspase-mediated pathways", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1487, 2000, pages 296 - 308, XP004277416, ISSN: 0005-2728, DOI: 10.1016/S1388-1981(00)00100-1
Attorney, Agent or Firm:
HIROTA Masanori (JP)
Download PDF: